- Altimmune Inc OLD Stocks plummeted afterwards Top-line results from its 12-week phase 1b study of pemvidutide in patients with non-alcoholic fatty liver disease (NAFLD).
- The study evaluated three dose levels, 1.2 mg, 1.8 mg and 2.4 mg.
- The study met its primary endpoint in all pemvidutide treatment groups.
- At the 1.8 mg dose (with and without diabetes), pemvidutide achieved a mean reduction in liver lipid content of 68.5%, with 94.4% of patients achieving a 30 percent reduction in liver lipids and 72.2% a 50 percent reduction. percent reduction in liver fat was achieved, and 55.6% of subjects achieved liver fat normalization.
- In addition, mean liver enzyme levels decreased in all subjects. In patients with a baseline serum ALT greater than 30 IU/L, levels decreased by more than 17 IU/L at all doses and by 27.0 IU/L in the 2.4 mg dose cohort.
- Related: Read why Altimmune stock plummeted after obesity study data.
- The study also met its key secondary endpoint in all pemvidutide treatment groups, with mean weight losses of 4.9% (placebo-adjusted 4.7%) in patients without diabetes and 4.4% in patients with diabetes (placebo-adjusted 3.9%), the one on 1.8. were reached or 2.4 mg doses.
- Pemvidutide has been reported to be generally well tolerated. Gastrointestinal events included most adverse events (AEs), mostly mild and transient.
- Two patients treated with pemvidutide discontinued treatment due to adverse events, both related to gastrointestinal intolerance.
- Price promotion: ALT shares are down 44.2% to $11.36 during the premarket session last check Wednesday.
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
